Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW.

J Clin Oncol. 2019 Dec 27:JCO1900895. doi: 10.1200/JCO.19.00895. [Epub ahead of print]

PMID:
31880950
2.

Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.

Stoner RC, Press RD, Maxson JE, Tyner JW, Dao KT.

Leukemia. 2019 Dec 16. doi: 10.1038/s41375-019-0688-1. [Epub ahead of print] No abstract available.

PMID:
31844143
3.

What do functional genomics tell us about pathogenesis of AML?

Tyner JW, Bottomly D, Wilmot B, McWeeney S.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101101. doi: 10.1016/j.beha.2019.101101. Epub 2019 Oct 18. Review.

PMID:
31779979
4.

Replication timing alterations in leukemia affect clinically relevant chromosome domains.

Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, Eaves CJ, Gilbert DM.

Blood Adv. 2019 Nov 12;3(21):3201-3213. doi: 10.1182/bloodadvances.2019000641.

5.

Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.

Choonoo G, Blucher AS, Higgins S, Boardman M, Jeng S, Zheng C, Jacobs J, Anderson A, Chamberlin S, Evans N, Vigoda M, Cordier B, Tyner JW, Kulesz-Martin M, McWeeney SK, Laderas T.

PLoS One. 2019 Oct 9;14(10):e0223639. doi: 10.1371/journal.pone.0223639. eCollection 2019.

6.

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW.

Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.

7.

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31.

PMID:
31366621
8.

SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells.

Sun QY, Ding LW, Johnson K, Zhou S, Tyner JW, Yang H, Doan NB, Said JW, Xiao JF, Loh XY, Ran XB, Venkatachalam N, Lao Z, Chen Y, Xu L, Fan LF, Chien W, Lin DC, Koeffler HP.

Oncogene. 2019 Aug;38(34):6196-6210. doi: 10.1038/s41388-019-0865-8. Epub 2019 Jul 22.

PMID:
31332289
9.

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW.

Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.

PMID:
31048320
10.

Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Mar 29;8. pii: e47174. doi: 10.7554/eLife.47174.

11.

FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Feb 5;8. pii: e40033. doi: 10.7554/eLife.40033. Erratum in: Elife. 2019 Mar 29;8:.

12.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.

Nat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.

13.

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR.

Leuk Res. 2019 Feb;77:42-50. doi: 10.1016/j.leukres.2018.11.010. Epub 2019 Jan 7.

14.

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.

Lim SL, Damnernsawad A, Shyamsunder P, Chng WJ, Han BC, Xu L, Pan J, Pravin DP, Alkan S, Tyner JW, Koeffler HP.

Haematologica. 2019 Jun;104(6):1209-1220. doi: 10.3324/haematol.2018.201483. Epub 2019 Jan 3.

15.

Two myeloid leukemia cases with rare FLT3 fusions.

Zhang H, Paliga A, Hobbs E, Moore S, Olson S, Long N, Dao KT, Tyner JW.

Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). pii: a003079. doi: 10.1101/mcs.a003079. Print 2018 Dec.

16.

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

Edwards DK 5th, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, Lind EF, Kaempf A, Mori M, Rosenberg M, d'Almeida A, Long N, Agarwal A, Sweeney DT, Loriaux M, McWeeney SK, Tyner JW.

Blood. 2019 Feb 7;133(6):588-599. doi: 10.1182/blood-2018-03-838946. Epub 2018 Nov 13.

PMID:
30425048
17.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

18.

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.

Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC.

Oncogene. 2019 Feb;38(8):1200-1210. doi: 10.1038/s41388-018-0508-5. Epub 2018 Sep 21.

19.

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW.

Leukemia. 2018 Sep;32(9):2025-2028. doi: 10.1038/s41375-018-0225-7. Epub 2018 Aug 6. No abstract available.

20.

Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW.

Sci Signal. 2018 Jul 17;11(539). pii: eaao5617. doi: 10.1126/scisignal.aao5617.

21.

ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer.

Guo X, Zhang Y, Mayakonda A, Madan V, Ding LW, Lin LH, Zia S, Gery S, Tyner JW, Zhou W, Yin D, Lin DC, Koeffler HP.

Oncogene. 2018 Nov;37(45):5939-5951. doi: 10.1038/s41388-018-0371-4. Epub 2018 Jul 6.

PMID:
29980791
22.

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.

Oncotarget. 2018 May 15;9(37):24576-24589. doi: 10.18632/oncotarget.25191. eCollection 2018 May 15.

23.

Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models.

Ouyang X, Barling A, Lesch A, Tyner JW, Choonoo G, Zheng C, Jeng S, West TM, Clayburgh D, Courtneidge SA, McWeeney SK, Kulesz-Martin M.

Cancer Biol Ther. 2018;19(10):921-933. doi: 10.1080/15384047.2018.1451285. Epub 2018 Aug 17.

24.

Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL.

Chow M, Gao L, MacManiman JD, Bicocca VT, Chang BH, Alumkal JJ, Tyner JW.

Oncogene. 2018 Sep;37(38):5221-5232. doi: 10.1038/s41388-018-0299-8. Epub 2018 May 30.

25.

Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia.

Jamalpour M, Li X, Gustafsson K, Tyner JW, Welsh M.

Tumour Biol. 2018 Apr;40(4):1010428318771472. doi: 10.1177/1010428318771472.

PMID:
29792386
26.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

27.

Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.

Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW.

J Biol Chem. 2018 May 11;293(19):7387-7396. doi: 10.1074/jbc.RA118.002417. Epub 2018 Mar 23.

28.

Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.

Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK 5th.

Haematologica. 2018 Aug;103(8):e351-e355. doi: 10.3324/haematol.2018.190926. Epub 2018 Mar 22. No abstract available.

29.

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.

Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ Jr, Druker BJ, Tyner JW, Gill PS.

Blood Adv. 2017 Aug 28;1(20):1635-1644. doi: 10.1182/bloodadvances.2017005694. eCollection 2017 Sep 12.

30.

A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia.

Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare T.

Haematologica. 2018 Feb;103(2):e87-e91. doi: 10.3324/haematol.2017.165282. Epub 2017 Dec 28. No abstract available.

31.

DNA distress creates lethal opportunity in MPN.

Tyner JW.

Blood. 2017 Dec 28;130(26):2814-2816. doi: 10.1182/blood-2017-11-813006. No abstract available.

PMID:
29284611
32.

Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.

Lue HW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, Nomura DK, Drake JM, Ritz A, Thomas GV.

Genes Dev. 2017 Oct 15;31(20):2067-2084. doi: 10.1101/gad.305292.117. Epub 2017 Nov 14.

33.

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.

Kanojia D, Garg M, Martinez J, M T A, Luty SB, Doan NB, Said JW, Forscher C, Tyner JW, Koeffler HP.

J Hematol Oncol. 2017 Nov 13;10(1):173. doi: 10.1186/s13045-017-0540-x.

34.

Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Dao KT, Tyner JW, Gotlib J.

Curr Hematol Malig Rep. 2017 Oct;12(5):432-441. doi: 10.1007/s11899-017-0413-y. Review.

PMID:
28983816
35.

Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.

Yuan J, Jiang YY, Mayakonda A, Huang M, Ding LW, Lin H, Yu F, Lu Y, Loh TKS, Chow M, Savage S, Tyner JW, Lin DC, Koeffler HP.

Cancer Res. 2017 Dec 1;77(23):6614-6626. doi: 10.1158/0008-5472.CAN-17-1143. Epub 2017 Sep 26.

36.

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.

37.

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.

Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX.

PLoS One. 2017 Jul 18;12(7):e0179558. doi: 10.1371/journal.pone.0179558. eCollection 2017.

38.

Kinase Inhibitor Screening in Myeloid Malignancies.

Tyner JW.

Hematol Oncol Clin North Am. 2017 Aug;31(4):693-704. doi: 10.1016/j.hoc.2017.04.004. Epub 2017 May 19. Review.

PMID:
28673396
39.

Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.

Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, Wilmot B, McWeeney SK, Kükenshöner T, Hantschel O, Tyner JW.

Cancer Res. 2017 Aug 15;77(16):4258-4267. doi: 10.1158/0008-5472.CAN-17-1052. Epub 2017 Jun 26.

40.

Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Deininger MWN, Tyner JW, Solary E.

Nat Rev Cancer. 2017 Jun 23;17(7):425-440. doi: 10.1038/nrc.2017.40. Review.

PMID:
28642604
41.

PlGF enhances TLR-dependent inflammatory responses in human mononuclear phagocytes.

Newell LF, Holtan SG, Yates JE, Pereira L, Tyner JW, Burd I, Bagby GC.

Am J Reprod Immunol. 2017 Oct;78(4). doi: 10.1111/aji.12709. Epub 2017 Jun 20.

42.

Recurrent cyclin D2 mutations in myeloid neoplasms.

Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney S, Edwards V DK, Druker BJ, Tyner JW.

Leukemia. 2017 Sep;31(9):2005-2008. doi: 10.1038/leu.2017.195. Epub 2017 Jun 20. No abstract available.

43.

Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.

Zhang H, Reister Schultz A, Luty S, Rofelty A, Su Y, Means S, Bottomly D, Wilmot B, McWeeney SK, Tyner JW.

Leukemia. 2017 Dec;31(12):2752-2760. doi: 10.1038/leu.2017.126. Epub 2017 Apr 25.

44.

Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.

Weber H, Valbuena JR, Barbhuiya MA, Stein S, Kunkel H, García P, Bizama C, Riquelme I, Espinoza JA, Kurtz SE, Tyner JW, Calderon JF, Corvalán AH, Grez M, Pandey A, Leal-Rojas P, Roa JC.

Oncotarget. 2017 Apr 18;8(16):26169-26184. doi: 10.18632/oncotarget.15410.

45.

BCL6 promotes glioma and serves as a therapeutic target.

Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, Doan N, Said JW, Yong WH, Watkins A, Yang H, Ding LW, Jiang YY, Tyner JW, Ching J, Kovalik JP, Madan V, Chan SL, Müschen M, Breunig JJ, Lin DC, Koeffler HP.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3981-3986. doi: 10.1073/pnas.1609758114. Epub 2017 Mar 29. Erratum in: Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4317.

46.

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A.

Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018.

47.

Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma.

Sun H, Lin DC, Cao Q, Pang B, Gae DD, Lee VKM, Lim HJ, Doan N, Said JW, Gery S, Chow M, Mayakonda A, Forscher C, Tyner JW, Koeffler HP.

Clin Cancer Res. 2017 Aug 1;23(15):4376-4387. doi: 10.1158/1078-0432.CCR-16-2185. Epub 2017 Mar 23.

48.

Integrating functional genomics to accelerate mechanistic personalized medicine.

Tyner JW.

Cold Spring Harb Mol Case Stud. 2017 Mar;3(2):a001370. doi: 10.1101/mcs.a001370. Review.

49.

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K.

Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146.

50.

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E, Chang BH, Brown TJ, Collins RH, Uhrig S, Balasubramanian GP, Bandapalli OR, Higi S, Eugster S, Voegeli P, Delorenzi M, Cario G, Loh ML, Schrappe M, Stanulla M, Kulozik AE, Muckenthaler MU, Saha V, Irving JA, Meisel R, Radimerski T, Von Stackelberg A, Eckert C, Tyner JW, Horvath P, Bornhauser BC, Bourquin JP.

Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.

Supplemental Content

Loading ...
Support Center